HANSOH PHARMA ANNOUNCES THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE(INEBILIZUMAB INJECTION) ACCEPTED BY NMPA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS

HANSOH PHARMA | AMEILE'S FOURTH INDICATION APPROVED FOR MARKETING, TARGETING POST-OPERATIVE ADJUVANT THERAPY FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

HANSOH PHARMA ANNOUNCES NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR NSNSCLC

UPLIZNA (INEBILIZUMAB) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

HANSOH PHARMA'S AMEILE MARKETING APPLICATION APPROVED FOR THIRD INDICATION

HANSOH PHARMA ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 2 STUDY ON HS-20137 (ANTI-IL-23P19 ANTIBODY) IN MODERATE TO SEVERE PSORIASIS AT AAD 2025 ANNUAL MEETING

HANSOH PHARMA ANNOUNCES NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR OSTEOSARCOMA

HANSOH PHARMA RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF HS-10561, A SMALL MOLECULE BTK INHIBITOR FOR CHRONIC SPONTANEOUS URTICARIA